Coget Julien, Pocard Marc
AP-HP, Hôpital Lariboisière, Service de chirurgie digestive et oncologique, 2, rue Ambroise-Paré 75010 Paris, France.
AP-HP, Hôpital Lariboisière, Service de chirurgie digestive et oncologique, 2, rue Ambroise-Paré 75010 Paris, France, AP-HP, Hôpital Lariboisière, Université, René-Diderot Paris 7, UMR Inserm 965-Paris 7, CART : carcinose angiogenèse et recherche translationnelle, 2, rue Ambroise-Paré 75010 Paris, France.
Bull Cancer. 2014 Apr;101(4):364-7. doi: 10.1684/bdc.2014.1917.
Sentinel lymph node (SLN) is a concept but also a technical possibility that can be studied and applied to almost all organs with cancer. For colorectal cancer surgery, some possibilities of using the SLN are possible, other implausible and some completely new especially aware of possible analysis of SLN by a molecular biology technique. The orientation of dissection or "lymph road mapping" can be designed for this case or the surgeon may want to limit his actions, particularly in patients with a history of colonic surgical resection, to keep the digestive function in maintaining vascular axes considered not involved in the metastatic process. The use of the single analysis of SLN to determine the positive or negative status of the cleaning has failed because of the frequency of false negatives in part to the size of colic advanced cancers at diagnosis. The use of "ultra-stading" by multiple section or exhaustion of the block, can lead to reconsider a stage N0 to N1 as a point, if the analysis technique remains in HES. Unlike the "ultra-stading" by RT- PCR or immunohistochemistry was even more discussed and seems not equivalent in terms of prognosis and therefore no giving formally justification for adjuvant therapy. Currently, a new technique for molecular biology, named "OSNA", allows an analysis of all the SLN in less than 45 minutes. It is therefore possible to obtain during surgery analysis of a node with the same level of information than traditional analysis using HES. If this node is positive and if the strategy in case of positive lymph nodes was determined prior for this patient, it is possible to anticipate this strategy and place after colectomy during the same anesthesia, venous access quickly to start postoperative chemotherapy. This new technique for analyzing lymph applied to the SLN opens a new potential application of this concept in digestive oncology.
前哨淋巴结(SLN)不仅是一个概念,更是一种技术可能性,几乎可应用于所有癌症器官的研究和实践。对于结直肠癌手术而言,运用SLN存在多种可能性,有些可行,有些难以实现,还有一些全新的可能性,特别是通过分子生物学技术对SLN进行分析。可针对该病例设计解剖方向或“淋巴路径绘图”,或者外科医生可能希望限制其操作,尤其是对于有结肠手术切除史的患者,以在维持被认为未参与转移过程的血管轴时保持消化功能。由于部分诊断时结肠进展期癌症的大小导致假阴性频率较高,仅通过对SLN进行单次分析来确定清扫的阳性或阴性状态已失败。通过多切片或整块组织耗尽进行“超分期”,如果分析技术仍采用苏木精-伊红染色(HES),可将N0期重新判定为N1期。与通过逆转录聚合酶链反应(RT-PCR)或免疫组化进行的“超分期”相比,后者讨论得更多,且在预后方面似乎并不等同,因此无法为辅助治疗提供正式依据。目前,一种名为“OSNA”的分子生物学新技术可在不到45分钟内对所有SLN进行分析。因此,在手术过程中有可能获得与使用HES的传统分析相同水平信息的淋巴结分析结果。如果该淋巴结为阳性,且针对该患者先前已确定了阳性淋巴结情况下的策略,则有可能提前规划该策略,并在结肠切除术后同一麻醉期间迅速建立静脉通路以开始术后化疗。这种应用于SLN的新型淋巴结分析技术为该概念在消化肿瘤学中开辟了新的潜在应用。